Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report
June 02 2020 - 8:00AM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
published its 2019 Environmental, Social and Governance (ESG)
Progress Report, demonstrating the company’s social impact and
responsibility performance. The report includes 2020 goals for
specific topics and clear alignment with the United Nations
Sustainable Development Goals. For the first time, an external
reviewer validated select report content.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200602005410/en/
The report details Teva’s 2019 efforts to lessen the burden of
existing and emerging health concerns. The company’s commitment to
address such challenges is reflected in its response to COVID-19 in
2020, including its efforts to ensure continuity of medicine
supply, prioritize the safety of its employees and work with
governments and public health organizations to advance
solutions.
“For Teva, ESG means working to improve the health of our
patients and communities and running an accountable business,” said
Kåre Schultz, President & CEO of Teva. “This report
demonstrates our actions to increase access to quality medicines,
support our employees, protect the environment and enhance
compliance, while keeping patients at the heart of what we do.”
Committed to bringing more quality, affordable treatments to
more people, Teva is improving health through its broad portfolio.
The company received more than 1,000 approvals for generic
medicines and 25 approvals for specialty medicines. Teva also
donated $246 million worth of medicines to patients across the
globe. With its partners, Teva implemented custom programs for
caregivers in seven countries. The company also received awards for
efforts to increase access to medicine and public health leadership
in supporting patients with multiple chronic conditions.
Teva recognizes its impact on the environment, working to reduce
pollution and ensure efficient use of energy and natural resources
across its facilities and supply chain. Teva reduced greenhouse gas
emissions by 17% from 2017, total waste by 13% from 2018 and total
energy consumption by 6% from 2018.
The company prioritizes the safety and well-being of its
employees and achieved its best-recorded internal workplace safety
performance to date.
As the world faces new health challenges, Teva remains committed
to improving the health of the nearly 200 million patients it
serves daily—and of communities around the world. Click here to
learn more about Teva’s 2019 ESG Progress Report. For more
information about Teva’s response to COVID-19, please see Teva’s
COVID-19 Updates and Resources.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to: our ability to impact and
effectively execute on our social, economic, environment and
governance related strategy and goals; our ability to successfully
compete in the marketplace; consolidation of our customer base and
commercial alliances among our customers; delays in launches of new
products and our ability to achieve expected results from
investments in our product pipeline; the effectiveness of our
patents and other measures to protect our intellectual property
rights; our substantial indebtedness, which may limit our ability
to incur additional indebtedness, engage in additional transactions
or make new investments; our business and operations in general,
including: duration, and geographic reach of the COVID-19 pandemic
and its impact on our business, financial condition, operations,
cash flows, and liquidity and on the economy in general;
interruptions in our supply chain, including due to potential
effects of the COVID-19 pandemic on our operations and business in
geographic locations impacted by the pandemic and on the business
operations of our customers and suppliers; adequacy of and our
ability to successfully execute and maintain the activities and
efforts related to the measures we have taken or may take in
response to the COVID-19 pandemic and associated costs therewith;
challenges associated with conducting business globally, including
adverse effects of the COVID-19 pandemic, political or economic
instability, major hostilities or terrorism; our ability to
attract, hire and retain highly skilled personnel; our ability to
develop and commercialize additional pharmaceutical products;
compliance with anti-corruption sanctions and trade control laws;
manufacturing or quality control problems; disruptions of
information technology systems; breaches of our data security and
privacy; compliance, regulatory and litigation matters, including
our ability to reach a final resolution of the remaining
opioid-related litigation; costs and delays resulting from the
extensive governmental regulation to which we are subject or delays
in governmental processing time including due to modified
government operations due to the COVID-19 pandemic and effects on
product and patent approvals; governmental investigations;
potential liability for patent infringement; product liability
claims; and other financial and economic risks including our
exposure to currency fluctuations and restrictions; and other
factors discussed in our Annual Report on Form 10-K for the year
ended December 31, 2019 and subsequent SEC filings, including in
the sections captioned "Risk Factors” and “Forward Looking
Statements.” Forward-looking statements speak only as of the date
on which they are made, and we assume no obligation to update or
revise any forward-looking statements or other information
contained herein, whether as a result of new information, future
events or otherwise. You are cautioned not to put undue reliance on
these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200602005410/en/
IR United States Kevin C. Mannix (215) 591-8912 Ran Meir
972 (3) 926-7516
PR United States Doris Li (973) 265-3752 Israel
Yonatan Beker 972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2024 to May 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From May 2023 to May 2024